Concepedia

Scott B. Hoyt

SB

Statistics

Publications

18

Citations

764

H-Index

15

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

National Center for Advancing Translational Sciences

Cincinnati Children's Hospital Medical Center

National Cancer Institute

University of Cincinnati Medical Center

Scott B. Hoyt is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and medicine.

ORCID

Publications per year

2000–2023

18

Publications

18

Analgesic Effects of a Substituted N-Triazole Oxindole (TROX-1), a State-Dependent, Voltage-Gated Calcium Channel 2 Blocker

Catherine Abbadie, Owen B. McManus, Shu-Yu Sun et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 98 citations

, , +17

Overcoming adaptive therapy resistance in AML by targeting immune response pathways

Katelyn Melgar, Morgan M. Walker, LaQuita M. Jones et al. · Science Translational Medicine · 2019 · 88 citations · Full text

, , +12

Discovery of a novel class of benzazepinone Nav1.7 blockers: Potential treatments for neuropathic pain

Scott B. Hoyt, Clare London, David J. Gorin et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 73 citations · Full text

, , +12

Characterization of the Substituted N-Triazole Oxindole TROX-1, a Small-Molecule, State-Dependent Inhibitor of Cav2 Calcium Channels

Andrew M. Swensen, James Herrington, Randal M. Bugianesi et al. · Molecular Pharmacology · 2011 · 66 citations

, , +17

A Peripherally Acting Nav1.7 Sodium Channel Blocker Reverses Hyperalgesia and Allodynia on Rat Models of Inflammatory and Neuropathic Pain

Erin McGowan, Scott B. Hoyt, Xiaohua Li et al. · Anesthesia & Analgesia · 2009 · 60 citations

, , +17

1–5 of 18